Johnson & Johnson will lay off a number of employees as part of a plan to revamp its diabetes arm, driven by ongoing challenges facing the broader industry sector.
Another cancer drug approval, another nosebleed-level price. Johnson & Johnson and Pharmacyclics' breakthrough drug Imbruvica (ibrutinib) won FDA approval yesterday for a rare form of lymphoma. Soon after, the companies said Imbruvica would be priced at more than $90 per pill. At four pills per day, that's about $130,000 per year.
The FDA has come through with an early approval of the BTK drug ibrutinib, a likely new cancer blockbuster from Pharmacyclics (and Johnson & Johnson.
Johnson & Johnson has reportedly wrapped up thousands of lawsuits over faulty hip-replacement products with a hefty $4 billion settlement.
The hunt for new biomarkers that can help guide the diagnosis and, eventually, some method of treatment for Alzheimer's has spurred Big Pharma and non-profit groups to fund a careful investigation into the disease's links to Down syndrome.
Johnson & Johnson reportedly negotiated a deal that will, at long last, resolve more than 7,500 lawsuits from patients who had faulty all-metal hips made by the company surgically removed. Bloomberg broke the news, citing three anonymous sources. If true, the settlement is astoundingly high, worth more than $4 billion.
The National Institute for Health and Care Excellence nixed Johnson & Johnson's Velcade as too expensive in comparison with the current standard therapies--at least as far as the current data can show.
Consumers who purchase over-the-counter products like Tylenol online sometimes receive items that are expired, defective, or even counterfeit. Now Johnson & Johnson and Amazon are in a fight over how much the online giant should be doing to keep that from happening.
When sold online, popular over-the-counter products like Tylenol can sometimes be expired, defective, or even counterfeit. Now Johnson & Johnson is in a spat with Amazon, contending that the online giant is not doing enough to stop that from happening.
Johnson & Johnson is gearing up for the next round of bidding for its Ortho Clinical Diagnostics unit, and the process has produced two unexpected allies bidding to snatch it up: Danaher and Blackstone Group.